Vetter Pharma

🚀 Building a website? Start with reliable WordPress hosting from MilesWeb →

Business news, market intelligence, and global industry analysis.

The Latest

Nvidia (NVDA) rises on Kyber denial but trails AMD and Broadcom as Rubin Ultra cadence questioned

GoldStone Resources (AIM: GRL) shares jump as Persistence Gold takes 21% stake in AIM miner

Nexsen (ASX: NXN) jumps as StrepSure validation path sharpens

Novartis agrees $1.5bn Myricx Bio deal as ADC platform race intensifies

EC clears €47m German aid for Vetter Pharma’s new manufacturing hub

EU approves €47m in German state aid for Vetter Pharma’s Saarlouis plant. Learn how this supports pharma jobs, injectables, and regional strategy.

byVenkatesh

December 10, 2025

Vetter announces major global expansion with investments in US and Germany

Vetter, a leading global contract development and manufacturing organization (CDMO), has unveiled significant expansion plans, which include relocating…

byPallavi Madhiraju

June 6, 2024

The Latest

Nvidia (NVDA) rises on Kyber denial but trails AMD and Broadcom as Rubin Ultra cadence questioned

GoldStone Resources (AIM: GRL) shares jump as Persistence Gold takes 21% stake in AIM miner

Nexsen (ASX: NXN) jumps as StrepSure validation path sharpens

Novartis agrees $1.5bn Myricx Bio deal as ADC platform race intensifies

EC clears €47m German aid for Vetter Pharma’s new manufacturing hub

Vetter announces major global expansion with investments in US and Germany

Nvidia (NVDA) rises on Kyber denial but trails AMD and Broadcom as Rubin Ultra cadence questioned

GoldStone Resources (AIM: GRL) shares jump as Persistence Gold takes 21% stake in AIM miner

Nexsen (ASX: NXN) jumps as StrepSure validation path sharpens

Novartis agrees $1.5bn Myricx Bio deal as ADC platform race intensifies

Knights Group revenue jumps 28% as KGH organic growth accelerates to 12%

Genesis Minerals (ASX: GMD) launches A$5.6bn Vault bid as Regis faces five-day test

Solstice to buy Element Solutions for $14.5bn as AI materials strategy faces investor test

Ipsen agrees €700m Memo Therapeutics deal as acquisition spree accelerates